|Articles|November 1, 2016
Schulman IRB to Launch COR Division
Schulman IRB will launch its new Central Oncology Review (COR) division this month.
Advertisement
Schulman IRB will launch its new Central Oncology Review (COR) division this month. The COR will feature a roster of oncology industry leaders, academics and distinguished scientists, each with a background in managing specialized oncology research.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Ensuring Digital Trial Platforms Work for Underserved CommunitiesSeptember 10th 2025
eClinical Technology: Misconceptions, Challenges, and OpportunitiesSeptember 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
3
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
4
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
